Clinical-Instrumental Study To Evaluate And Compare The Efficacy And Tolerability Of Two Emollients Products In Atopic Dermatitis
NCT ID: NCT06930365
Last Updated: 2025-04-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
64 participants
INTERVENTIONAL
2024-12-09
2025-07-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Signs and symptoms of AD are associated with a compromised immune system, a defective skin barrier, a cutaneous dysbiosis and overall inflammatory status.
The aim of the study is to evaluate and compare the efficacy and tolerability of two face and body cream products, new emollient versus placebo, in used over the course of 5 weeks as a replacement of usual or any emollient by female and male subjects with atopic dermatitis.
This is an interventional, single-center, double-blind, randomized and comparative study.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Description of the Population With Moderate to Severe Atopic Dermatitis, Treated by Systemic Treatments and Needs Regarding Emollients
NCT06983561
Efficacy Evaluation and Cutaneous Acceptibility of a Dermocosmetic Product on Subjects Suffering of Atopic Dermatisis.
NCT06756438
Effect of an Emollient Cream Containing a Milk Bioactive Peptide on Clinical Signs, Pruritus and Bacterial Colonization of Mild Atopic Dermatitis Skin Lesions in Pediatric Population
NCT07259343
Evaluating Results of Regularly Applied Emollient - Spray in Atopic Dermatitis Therapy
NCT02763722
Impact of the Daily Use of Emollient on Corticosteroids Consumption in Patients With Atopic Dermatitis
NCT05644691
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Amr 1: New Emollient
Study product, Emollient. Face and body
Anti-itching and repairing treatment. Emollient.
Anti-itching and repairing treatment. Emollient.
Arm 2: Placebo
Product 2: Placebo, Emollient. face and body
Emollient cream
Emollient cream
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Anti-itching and repairing treatment. Emollient.
Anti-itching and repairing treatment. Emollient.
Emollient cream
Emollient cream
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participant aged between 18 years old and more included,
* All ethnicities
* Phototype II to IV
* Participant with all skin types, sensitive or not sensitive,
* 44 subjects having a rash of eczema (SCORAD between 25 and 50) with at least 1 lesional area requiring topical corticosteroid treatment,
* 22 healthy subjects (without any dermatological pathology nor disorder),
* 44 participants having whitened eczema lesions at Dx (between 5 to 10 days) after the topical corticosteroid treatment,
* Participants having signed their written Informed Consent form (ICF) for their participation in the study and a photograph authorization,
* Participant able to comply with the protocol and follow protocol's constraints and specific requirements.
* Known pregnancy, participant breastfeeding, or not willing to take necessary precautions to avoid a pregnancy during the study,
* Participant with dermatological problems in the test areas other than atopic dermatitis,
* Pharmacological treatments (topic or systemic) other than topical corticosteroids, known to interfere with skin metabolism / physiology. In particular, no antibiotics taken within 4 weeks preceding the inclusion, nor anti- inflammatories taken within 2 weeks before the inclusion
* Participant being deprived of liberty by judicial or administrative decision, or under guardianship,
* Participant being linguistically or psychologically incapable of signing informed consent and unable to comply with the protocol requirements,
* Participant who has a relevant change in his state of health since registered in the LTD "Health" Database (change incompatible with inclusion in the study),
* Participant currently enrolled in another similar clinical study or in an exclusion period of a study,
* Participant having a skin recently exposed to sunlight (natural or artificial) and / or having applied a self-tanner on the application areas and /or tanning activator (dietary supplement) within 2 weeks preceding the inclusion.
* Participant having bathed in a swimming pool within 1 week preceding the inclusion or planning to bath in a swimming pool during the study.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
NAOS Les Laboratoires
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ltd Health
Batumi, Adjara, Georgia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RC2024/PSaib+/GE
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.